FHTX stock icon

Foghorn Therapeutics

6.57 USD
+0.04
0.61%
At close Dec 6, 4:00 PM EST
1 day
0.61%
5 days
-18.49%
1 month
-28.90%
3 months
-12.75%
6 months
5.46%
Year to date
1.86%
1 year
47.64%
5 years
-63.74%
10 years
-63.74%
 

About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Employees: 116

0
Funds holding %
of 6,794 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

318% more call options, than puts

Call options by funds: $92K | Put options by funds: $22K

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

64% more capital invested

Capital invested by funds: $227M [Q2] → $372M (+$145M) [Q3]

35% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 20

10% more funds holding

Funds holding: 72 [Q2] → 79 (+7) [Q3]

0.88% more ownership

Funds ownership: 71.41% [Q2] → 72.29% (+0.88%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$9
37%
upside
Avg. target
$9
37%
upside
High target
$9
37%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Morgan Stanley
Vikram Purohit
40% 1-year accuracy
2 / 5 met price target
37%upside
$9
Equal-Weight
Maintained
24 Sept 2024

Financial journalist opinion

Based on 3 articles about FHTX published over the past 30 days

Positive
Zacks Investment Research
1 week ago
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?
Neutral
GlobeNewsWire
3 weeks ago
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7th Annual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Negative
Zacks Investment Research
1 month ago
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
Neutral
GlobeNewsWire
1 month ago
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Primary target patient population for the FHD-909 Phase 1 trial is  non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn's selective SMARCA2 oncology program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Lilly CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- October 10, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the first patient has been dosed with FHD-909 (LY4050784) in the Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population.
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Neutral
GlobeNewsWire
2 months ago
Foghorn Therapeutics to Participate in the BMO Oncology Summit
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Foghorn Therapeutics to Participate in the BMO Oncology Summit
Positive
Zacks Investment Research
2 months ago
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
Neutral
GlobeNewsWire
3 months ago
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Anna Rivkin, Ph.D., will join the company as Chief Business Officer (CBO), on September 3, 2024. Dr. Rivkin brings over two decades of expertise in a broad spectrum of complex business transactions across multiple disease areas.
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
The consensus price target hints at an 81.2% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
Charts implemented using Lightweight Charts™